CLINTEC INTERNATIONAL TO LOCATE GLOBAL HEADQUARTERS IN SCOTLAND CREATING UP TO 240 NEW JOBS

28 November 2007: Contract clinical research services company ClinTec International today announces that it is to locate its new global corporate headquarters in Glasgow, creating up to 240 new jobs over the next three years. ClinTec International already has operations in all key and emerging clinical research markets globally, and the new headquarters will add additional strength and skilled talent to support the company’s ambitious growth plans in a market currently worth an estimated $14 billion per year.

ClinTec International provides specialist clinical consultancy to national and global pharmaceutical and biotech companies. The company develops and implements the clinical trials of drugs designed to tackle some of most acute diseases in the world today.

The new headquarters will be the company’s base for its world wide human resources, finance, IT, marketing, legal, corporate development, and sales functions as well as housing a team of clinical professionals who will manage the implementation of global clinical trials.

Minister for Enterprise, Energy and Tourism, Jim Mather, welcomed the announcement:

“This is great news for Glasgow and a tribute to Scotland’s strengths in life sciences. Our new economic strategy means that Scotland’s public sector is better able than ever to support our aim of increased sustainable growth.

“We are creating the kind of supportive business environment that I believe will see many more companies follow ClinTec’s example in locating its global HQ here in Scotland. And we are building on our clear strengths in life sciences such as our strong cohesive academic base, the quality of our research, our health records and our skilled motivated people, all of which ClinTec and many more global companies clearly recognise and value.”

The new project is being supported by a Regional Selective Assistance Grant of £1,343,000.

Dr Rabinder Buttar, President and Founder of ClinTec said: “We have reached an important milestone in the 10 years of our organisation and I am pleased that our Scottish operations will play a central role as we develop into a major global player in contract clinical research. From the key universities and research institutes in Scotland we will recruit, train and develop a highly skilled talent pool to work on our global initiatives meeting the high standards expected by us and our clients in the pharmaceutical and biotech industry.“

Lena Wilson, Chief Operating Officer of Scottish Enterprise, said; “ClinTec's new project is very important for the life sciences sector in Scotland as it will enhance Scotland's growing international reputation in attracting successful and ambitious international contract research organisations.

“The market for contract research organisations has been expanding over the last decade as pharmaceutical and biotech companies look to mitigate risk in their development programmes and industry analysts expect this market to grow to $20 billion in value by 2010.”

Ends

For further information, please contact:

Stephen Sharp, Senior Media Relations Executive, Scottish Enterprise
Tel: 0141 228 7364
Mobile: 07786 126 629
Email: stephen.sharp@scotent.co.uk

Bobby Bal, Senior Director Corporate Development, ClinTec International
Mobile : 0774 832 6128
Email : bbal@clintec.com
www.clintec.com


Notes to editors

About ClinTec International
ClinTec International is a full service global clinical research organization, which was founded in 1997 by Dr Rabinder Buttar, the company’s President and Founder. ClinTec International has a presence in more than 30 developed and emerging countries, covering Western Europe, Central & Eastern Europe, Middle East and North Africa, Central and South Africa, Latin America, India and the US. In addition to ClinTec’ vast expertise in oncology, it has also conducted over a 150 clinical trials in many other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused’ approach to clinical research ensures an added advantage to the drug development process. ClinTec’s range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Pharmacovigilance, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

About Regional Selective Assistance
Regional Selective Assistance (RSA) is the main national scheme of financial assistance to industry. It provides discretionary grants for investment projects that will create or safeguard jobs in Assisted Areas – areas designated for regional aid under European community law. The scheme is administered by the RSA Scotland unit of the Scottish Executive. Payment of RSA is made in instalments, typically over several years, provided that job and project expenditure targets are met. The amount quoted above represent the maximum grant potentially payable if the project is satisfactorily completed. Job numbers are based on the firms’ forecast at the time a grant is offered, and are subject to change depending on future economic conditions and other factors affecting the business concerned. For further information on the scheme, go to www.rsascotland.gov.uk .

About Scottish Development International
Scottish Development International works to attract inward investment and knowledge to Scotland in order to help the economy grow. SDI also works to help Scottish companies do more business overseas and to promote Scotland as a good place to live, work and do business. It is jointly operated by the Scottish Government and Scottish Enterprise. Its work is guided by the Scottish Government’s strategy for economic development in Scotland. www.sdi.co.uk